KIGALI, Rwanda and ADDIS ABABA, Ethiopia -- Bio Usawa’s Chief Executive Officer, Dr. Menghis, and Chief Operating Officer, Dr. Patrick Lukulay, held a strategic meeting with the Africa CDC’s Local Production Coordinator and team at their headquarters.

The discussion centered on Bio Usawa’s mission to establish local manufacturing capabilities for monoclonal antibodies in Africa, with an initial focus on Rwanda and plans for future continental expansion. Bio Usawa further offered its team’s expertise to support the Africa CDC’s capacity-building initiatives in biomanufacturing and clinical trials.

In today’s era of escalating tariff wars and pharmaceutical trade disruptions, reliance on imports has become an unacceptable risk. Africa must build self-sufficiency in the manufacturing of both essential NCD and non-NCD products. Bio Usawa sees this challenge as a unique opportunity—demonstrating that Africa can lead with world-class science, competitive manufacturing, and supply chain resilience. But to seize this moment, bold investment is required. Development banks, pension funds, and private capital must channel resources into African-led companies like Bio Usawa that are positioned to scale rapidly and deliver locally made, globally competitive biologics. The cost of delay will be measured in both economic vulnerability and lives lost.

The Africa CDC affirmed that Bio Usawa’s objectives are strongly aligned with its own mission to develop medical countermeasures for pandemic preparedness and to build a robust African biomanufacturing workforce.

Both parties agreed to collaborate in advancing Africa’s health security and sovereignty, with a shared goal of reducing the continent’s dependence on imported critical medicines, especially during emergencies.

About Bio Usawa, Inc.

Bio Usawa is Rwanda's leading biotechnology company dedicated to democratizing access to life-saving biopharmaceuticals across Africa. Founded on the principle that geographic location should not determine healthcare outcomes, the company specializes in developing and manufacturing affordable, high-quality monoclonal antibodies targeting cancer, diabetes complications, infectious diseases, and autoimmune conditions. Bio Usawa's leadership team brings decades of experience from leading global biotech companies and international regulatory agencies.